Lescol

• Free Radical Scavengers
• Antioxidants
• Anticholesteremic Agents
• HMG-CoA Reductase Inhibitors
• ATC:C10AA04

• Cranoc
• Fluindostatin
• Fluindostatin: Lescol
• Fluvastatina [Inn-Spanish]
• Fluvastatine [Inn-French]
• Fluvastatinum [Inn-Latin]
• Lescol
• Lescol XL

• No information avaliable

C₂₄H₂₆FNO₄

http://www.rxlist.com/cgi/generic2/fluvastatinxl.htm

Lescol FDA

F. G. Kathawala, U.S. Pat. 4,739,073 (1988)

411.466 g/mol

194-197^oC

0.46 mg/L

Solid

4.98

Capsules; Tablets (extended-release)

For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia

Fluvastatin, the first synthetically-prepared HMG-CoA reductase inhibitor, is used as an antilipemic to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) and to slow the progression of coronary atherosclerosis in patients with coronary artery disease. Although similar to lovastatin, simvastatin, and pravastatin, Fluvastatin has a shorter half-life, no active metabolites, extensive protein binding, and minimal CSF penetration.

24% (range 9%-50%).

Variety of GI complaints and an increase in transaminase values (i.e., SGOT and SGPT).

PATIENT INFORMATION

Patients should be advised to report promptly unexplained muscle pain, tenderness or
weakness, particularly if accompanied by malaise or fever.

Women should be informed that if they become pregnant while receiving Lescol or Lescol
XL the drug should be discontinued immediately to avoid possible harmful effects on a
developing fetus from a relative deficit of cholesterol and biological products derived
from cholesterol. In addition, Lescol or Lescol XL should not be taken during nursing.

Humans and other mammals